PD-1治疗晚期原发性肝癌的临床效果与安全性

Clinical Observation of Anti-PD-1 Antibody in the Treatment of Advanced Primary Liver Cancer

目的:本研究通过回顾性分析PD-1在晚期原发性肝癌治疗中的临床效果及安全性。方法:通过回顾性分析2019年1月-2020年1月本院收治的晚期原发性肝癌15例,进行PD-1静脉注射[200 mg/次,每21天1次(Q3W)]治疗,直至病情进展,总结临床疗效、生存情况、不良反应发生情况。结果:PD-1在晚期肝癌患者治疗中的客观缓解率是13.3%,疾病控制率是60.0%,无进展生存期是为4.4个月,总生存期是7.8个月。患者最常见不良反应为皮疹和肠道反应,G3~4不良反应为皮疹。结论:PD-1在晚期原发性肝癌治疗中有一定临床疗效,不良反应可耐受。

Objective:This study retrospectively analyzed the clinical efficacy and safety of Anti-PD-1 antibody in the treatment of advanced primary liver cancer.Method:A total of 15 patients with advanced primary liver cancer admitted to our hospital from January 2019 to January 2020 were retrospectively analyzed.Anti-PD-1 antibody was injected intravenously[200 mg/time,21 days is one cycle (Q3W)]until the disease progressed.The clinical efficacy,survival and adverse reactions were summarized.Result:The objective response rate (ORR) of Anti-PD-1 antibody was 13.3%,the disease control rate was 60.0%,the median PFS was 4.4 months,and the median OS was 7.8 months.The most common adverse reactions were rash and intestinal reactions,while G3-4 adverse reactions were rash.Conclusion:Anti-PD-1 antibody has a certain clinical effect in the treatment of advanced primary liver cancer,and its adverse reactions are tolerable.